Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing 5'-Ara-C-O-amino ester

A technology of amino acid esters and cytarabine, which is applied in the direction of drug combinations, medical preparations containing active ingredients, antineoplastic drugs, etc. poor permeability

Inactive Publication Date: 2016-02-03
KUNMING JIDA PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there are some disadvantages in intravenous administration: the drug is highly irritating to the skin and subcutaneous tissue. If it leaks out of the vein, it can cause phlebitis and surrounding tissue necrosis; the injection of foreign particles or air can cause embolism, and drug contamination can easily cause infection; Directly entering the blood, prone to various side reactions such as allergies, poisoning, etc.; too fast to overload the circulation, prone to acute heart failure, pulmonary edema and other critical illnesses
[0006] However, the molecular polarity of cytarabine is very large, which leads to poor membrane permeability of the small intestine, and is easily inactivated by deamination of cytosine nucleoside deaminase in the gastrointestinal mucosa and liver, resulting in the oral bioavailability of cytarabine very low (about 20%)
But there is no report about the oral preparation of this class of prodrugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing 5'-Ara-C-O-amino ester
  • Pharmaceutical composition containing 5'-Ara-C-O-amino ester
  • Pharmaceutical composition containing 5'-Ara-C-O-amino ester

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] tablet

[0034] Cytarabine 5'-0-L-valine ester hydrochloride 30g lactose 60g microcrystalline cellulose 25g Crospovidone 15g citric acid 1g Magnesium stearate 2g production 1000 pieces

[0035] Preparation Process

[0036] Pass cytarabine 5'-0-L-valine ester hydrochloride through a 80 mesh sieve, mix the main ingredient with other excipients except magnesium stearate, add appropriate amount of water, make soft material, and granulate with 18 mesh , dried at 60 degrees, 16 whole grains, mixed with magnesium stearate, and compressed into tablets.

Embodiment 2

[0038] tablet

[0039] Cytarabine 5'-0-D-valine ester hydrochloride 15g Mannitol 60g pregelatinized starch 25g Cross-linked polyvinylpyrrolidone 15g tartaric acid 1.5g Magnesium stearate 2g production 1000 pieces

[0040] Preparation process: with embodiment 1

Embodiment 3

[0042] tablet

[0043] Cytarabine 30g lactose 60g hypromellose 25g Sodium carboxymethyl starch 15g citric acid 1g Magnesium stearate 2g production 1000 pieces

[0044] Preparation process: with embodiment 1

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition for oral pharmaceuticals, using 5'-Ara-C-O-amino ester or its salt as an active ingredient. According to dissolution testing, a second method in the appendix XC of the second part of Chinese pharmacopoeia edition 2010, the dissolution of the active ingredient of the composition is higher than or equal to 80% in 15 min, by using 900 ml of water as a dissolving medium at a rotation speed of 50 rpm. Organic acids are added into a prescription of the composition, a certain ratio of the organic acids is maintained, and thus the stability of pharmaceutical composition is substantially improved. A short-term stability test presents no increase in impurity.

Description

technical field [0001] The present invention relates to the field of pharmaceutical compositions comprising cytarabine prodrugs as active ingredients. More specifically, the present invention relates to an oral pharmaceutical composition, which contains cytarabine 5'-0-amino acid ester as an active ingredient, and the absolute bioavailability after oral administration can reach more than 60%. Background technique [0002] The chemical name of cytarabine is 1-β-D-arabinofuranosyl-4-amino-2(1H)-cytosine. Cytarabine can be converted into active cytarabine triphosphate in the body. Cytarabine triphosphate inhibits DNA polymerase and infiltrates DNA in a small amount, thereby preventing DNA synthesis and inhibiting cell growth. Cytarabine is one of the most effective drugs clinically used in the treatment of acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. Cytarabine also has antiviral effects and is used to treat various herpes virus infections. In nervous s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/12A61K31/7068A61K9/20A61P35/02A61P35/00A61P31/22
Inventor 王立江冯朴纯赵玉兰张晓
Owner KUNMING JIDA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products